Screener
Oruka Therapeutics, Inc. ORKA Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other non-current assets | — | (60) |
| Accounts payable | (493) | 83 |
| Accrued expenses and other current liabilities | (1,304) | 2,317 |
| Operating lease liability | (125) | (21) |
| Related party accounts payable and other current liabilities | 2,995 | (5,205) |
| Net cash used in operating activities | (23,578) | (20,869) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (73) | (13) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Oruka Therapeutics, Inc. (ORKA) reported short- and long-term operating lease liabilities of -$125K in Q1 2026.
- How has Oruka Therapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Oruka Therapeutics, Inc.'s short- and long-term operating lease liabilities decreased by 495.2% year-over-year, from -$21K to -$125K.
- What does short- and long-term operating lease liabilities mean?
- Measures the net change in the present value of future lease payments for operating assets. This metric is essential for understanding the company's long-term fixed commitments and the impact of lease accounting standards on the balance sheet.
Ask your AI about Oruka Therapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude